Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma.

Klein M, Lotem M, Peretz T, Zwas ST, Mizrachi S, Liberman Y, Chisin R, Schachter J, Ron IG, Iosilevsky G, Kennedy JA, Revskaya E, de Kater AW, Banaga E, Klutzaritz V, Friedmann N, Galun E, Denardo GL, Denardo SJ, Casadevall A, Dadachova E, Thornton GB.

J Skin Cancer. 2013;2013:828329. doi: 10.1155/2013/828329. Epub 2013 Jan 10.

2.

Concepts, consequences, and implications of theranosis.

DeNardo GL, DeNardo SJ.

Semin Nucl Med. 2012 May;42(3):147-50. doi: 10.1053/j.semnuclmed.2011.12.003. Review.

PMID:
22475423
3.

Pretherapy prediction of nephrotoxicity after peptide radionuclide receptor therapy (PRRT).

Denardo GL, Macey DJ.

Cancer Biother Radiopharm. 2010 Oct;25(5):507-9. doi: 10.1089/cbr.2010.0875. Epub 2010 Sep 19. No abstract available.

PMID:
20849311
4.

Health care in the United States in 2009: both sides of the "counter".

DeNardo GL, DeNardo SJ.

Cancer Biother Radiopharm. 2009 Oct;24(5):515-7. doi: 10.1089/cbr.2009.0702. No abstract available.

PMID:
19877880
5.

Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia.

DeNardo GL, Mirick GR, Hok S, DeNardo SJ, Beckett LA, Adamson GN, Balhorn RL.

Int J Oncol. 2009 Feb;34(2):511-6.

PMID:
19148487
6.

Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging.

DeNardo GL, Natarajan A, Hok S, Mirick G, DeNardo SJ, Corzett M, Sysko V, Lehmann J, Beckett L, Balhorn R.

Cancer Biother Radiopharm. 2008 Dec;23(6):783-96. doi: 10.1089/cbr.2008.0589.

7.

Update: Turning the heat on cancer.

DeNardo GL, DeNardo SJ.

Cancer Biother Radiopharm. 2008 Dec;23(6):671-80. doi: 10.1089/cbr.2008.0591. Review.

8.

Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

DeNardo GL, DeNardo SJ, Balhorn R.

Cancer Biother Radiopharm. 2008 Aug;23(4):383-97. doi: 10.1089/cbr.2007.0523-U.

9.

Development of TNKase-specific cleavable peptide-linked radioimmunoconjugates for radioimmunotherapy.

Natarajan A, Kumaresan PR, Denardo SJ, Denardo GL, Mirick G, Lam KS.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4802-5. doi: 10.1016/j.bmcl.2008.07.097. Epub 2008 Jul 30.

PMID:
18701282
10.

Targeted radionuclide therapy.

Williams LE, DeNardo GL, Meredith RF.

Med Phys. 2008 Jul;35(7):3062-8.

11.

Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice.

Dadachova E, Revskaya E, Sesay MA, Damania H, Boucher R, Sellers RS, Howell RC, Burns L, Thornton GB, Natarajan A, Mirick GR, DeNardo SJ, DeNardo GL, Casadevall A.

Cancer Biol Ther. 2008 Jul;7(7):1116-27. Epub 2008 Apr 28.

PMID:
18535406
12.

NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics.

Natarajan A, Gruettner C, Ivkov R, DeNardo GL, Mirick G, Yuan A, Foreman A, DeNardo SJ.

Bioconjug Chem. 2008 Jun;19(6):1211-8. doi: 10.1021/bc800015n. Epub 2008 Jun 3.

13.

Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells.

Lehmann J, Natarajan A, Denardo GL, Ivkov R, Foreman AR, Catapano C, Mirick G, Quang T, Gruettner C, Denardo SJ.

Cancer Biother Radiopharm. 2008 Apr;23(2):265-71. doi: 10.1089/cbr.2007.0411.

PMID:
18454696
14.

Development of multivalent radioimmunonanoparticles for cancer imaging and therapy.

Natarajan A, Xiong CY, Gruettner C, DeNardo GL, DeNardo SJ.

Cancer Biother Radiopharm. 2008 Feb;23(1):82-91. doi: 10.1089/cbr.2007.0410.

PMID:
18298332
15.

The conundrum of personalized cancer management, drug development, and economics.

DeNardo GL.

Cancer Biother Radiopharm. 2007 Dec;22(6):719-21. No abstract available.

PMID:
18158762
16.

Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia.

Balhorn R, Hok S, Burke PA, Lightstone FC, Cosman M, Zemla A, Mirick G, Perkins J, Natarajan A, Corzett M, DeNardo SJ, Albrecht H, Gregg JP, DeNardo GL.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5621s-5628s.

17.

Selecting an intervention time for intravascular enzymatic cleavage of peptide linkers to clear radioisotope from normal tissues.

Siantar CL, DeNardo GL, Lam K, Yuan A, Daly T, DeNardo SJ.

Cancer Biother Radiopharm. 2007 Aug;22(4):556-63.

PMID:
17803451
18.

Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules.

Albrecht H, Cosman M, Ngu-Schwemlein M, Corzett M, Curran KW, Dolan C, Fang X, DeNardo SJ, DeNardo GL, Balhorn R.

Cancer Biother Radiopharm. 2007 Aug;22(4):531-42.

PMID:
17803448
19.

Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.

Schillaci O, DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, O'Donnell RT, Lamborn KR.

Cancer Biother Radiopharm. 2007 Aug;22(4):521-30.

PMID:
17803447
20.

Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma.

DeNardo GL, Hok S, Van Natarajan A, Cosman M, DeNardo SJ, Lightstone FC, Mirick GR, Yuan A, Perkins J, Sysko VV, Lehmann J, Balhorn RL.

Int J Oncol. 2007 Oct;31(4):729-40.

21.

Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma.

DeNardo GL, Natarajan A, Hok S, Perkins J, Cosman M, DeNardo SJ, Lightstone FC, Mirick GR, Miers LA, Balhorn RL.

J Nucl Med. 2007 Aug;48(8):1338-47. Epub 2007 Jul 13.

22.

Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers.

Albrecht H, Denardo GL, Denardo SJ.

Q J Nucl Med Mol Imaging. 2007 Dec;51(4):304-13. Epub 2007 May 1. Review.

23.

Construction of di-scFv through a trivalent alkyne-azide 1,3-dipolar cycloaddition.

Natarajan A, Du W, Xiong CY, DeNardo GL, DeNardo SJ, Gervay-Hague J.

Chem Commun (Camb). 2007 Feb 21;(7):695-7. Epub 2006 Nov 28.

PMID:
17392953
24.

Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia.

Hok S, Natarajan A, Balhorn R, DeNardo SJ, DeNardo GL, Perkins J.

Bioconjug Chem. 2007 May-Jun;18(3):912-21. Epub 2007 Mar 21.

PMID:
17373772
25.

Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice.

DeNardo SJ, DeNardo GL, Natarajan A, Miers LA, Foreman AR, Gruettner C, Adamson GN, Ivkov R.

J Nucl Med. 2007 Mar;48(3):437-44.

26.

Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells.

West J, Perkins J, Hok S, Balhorn R, Lightstone FC, Cosman M, DeNardo SJ, DeNardo GL.

Cancer Biother Radiopharm. 2006 Dec;21(6):645-54.

PMID:
17257080
27.

Targeted radionuclide therapy for solid tumors: an overview.

DeNardo SJ, Denardo GL.

Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S89-95. Review.

PMID:
16979448
28.

Cure of incurable lymphoma.

DeNardo GL, Sysko VV, DeNardo SJ.

Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S46-56. Review.

PMID:
16979440
29.

Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.

Lehmann J, DeNardo GL, Yuan A, Shen S, O'Donnell RT, Richman CM, DeNardo SJ.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1192-8. Epub 2006 Sep 11.

PMID:
16965873
30.

Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.

Burke PA, Gregg JP, Bakhtiar B, Beckett LA, Denardo GL, Albrecht H, De Vere White RW, De Nardo SJ.

Int J Oncol. 2006 Jul;29(1):49-55.

PMID:
16773184
31.

Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding.

Xiong CY, Natarajan A, Shi XB, Denardo GL, Denardo SJ.

Protein Eng Des Sel. 2006 Aug;19(8):359-67. Epub 2006 Jun 7.

PMID:
16760193
32.
33.

Editorial: "right place, wrong place": extravasation of therapeutic drug for molecular targeted radiotherapy.

Denardo GL.

Cancer Biother Radiopharm. 2006 Apr;21(2):85-7. No abstract available.

PMID:
16706628
34.

MINERVA: a multi-modality plugin-based radiation therapy treatment planning system.

Wemple CA, Wessol DE, Nigg DW, Cogliati JJ, Milvich M, Fredrickson CM, Perkins M, Harkin GJ, Hartmann-Siantar CL, Lehmann J, Flickinger T, Pletcher D, Yuan A, DeNardo GL.

Radiat Prot Dosimetry. 2005;116(1-4 Pt 2):202-7.

PMID:
16604627
35.
36.

Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies.

Azinovic I, DeNardo GL, Lamborn KR, Mirick G, Goldstein D, Bradt BM, DeNardo SJ.

Cancer Immunol Immunother. 2006 Dec;55(12):1451-8. Epub 2006 Feb 22.

PMID:
16496145
37.

Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.

Shen S, DeNardo GL, Yuan A, Hartmann-Siantar C, O'Donnell RT, DeNardo SJ.

Cancer Biother Radiopharm. 2005 Dec;20(6):662-70.

PMID:
16398618
38.

Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograft.

Miers L, DeNardo SJ, Lamborn K, DeNardo GL.

Cancer Biother Radiopharm. 2005 Dec;20(6):614-9.

PMID:
16398613
39.

Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.

DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A, Gregg JP, O'Donnell RT, DeNardo GL.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7187s-7194s.

40.

Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer.

Ivkov R, DeNardo SJ, Daum W, Foreman AR, Goldstein RC, Nemkov VS, DeNardo GL.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7093s-7103s.

41.

Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy.

DeNardo SJ, DeNardo GL, Miers LA, Natarajan A, Foreman AR, Gruettner C, Adamson GN, Ivkov R.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7087s-7092s.

42.
43.

High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.

Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL.

Clin Cancer Res. 2005 Aug 15;11(16):5920-7.

44.

Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).

DeNardo GL.

Semin Nucl Med. 2005 Jul;35(3):202-11.

PMID:
16098294
45.

Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.

Shen S, DeNardo SJ, Richman CM, Yuan A, Siantar CH, O'Donnell RT, Kroger LA, DeNardo GL.

J Nucl Med. 2005 Jun;46(6):1034-41.

46.
47.

Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.

Natarajan A, Xiong CY, Albrecht H, DeNardo GL, DeNardo SJ.

Bioconjug Chem. 2005 Jan-Feb;16(1):113-21.

PMID:
15656582
48.

A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words.

Mirick GR, Bradt BM, Denardo SJ, Denardo GL.

Q J Nucl Med Mol Imaging. 2004 Dec;48(4):251-7. Review.

49.

Radiometals as payloads for radioimmunotherapy for lymphoma.

DeNardo GL, Kennel SJ, Siegel JA, Denardo SJ.

Clin Lymphoma. 2004 Oct;5 Suppl 1:S5-10. Review.

PMID:
15498149
50.

New directions in radioimmunotherapy of non-Hodgkin's lymphoma.

DeNardo GL.

Clin Lymphoma. 2004 Oct;5 Suppl 1:S4. No abstract available.

PMID:
15498148

Supplemental Content

Loading ...
Support Center